| | | | |

Mesothelioma Surgery and the Threat of Opioid Addiction

A new study of opioid addiction among lung cancer patients may have implications for pleural mesothelioma patients who are considering surgery.

The study, published this month in JAMA Oncology, finds that patients treated with more invasive surgical techniques are more likely to become chronic opioid users than those who have less invasive surgery.

Opioids Are ‘Standard of Care’ for Lung Surgery Patients

Researchers at Mount Sinai Medical Center in New York studied the cases of nearly 4,000  people from the SEER Medicare database who had some type of surgery for non-small cell lung cancer, a type of cancer that shares many commonalities with the lung-related asbestos cancer, pleural mesothelioma.

Some of the lung cancer patients studied underwent open thoracic surgery while others underwent video-assisted thoracoscopic surgery (VATS), a less invasive option that involves an internal camera and a few small incisions. About 71 percent of patients were given prescriptions for opioid medications to deal with post-surgical pain.

“While the current standard of care is to prescribe opioids at discharge, this treatment is intended as short-term pain control, not to exceed a few weeks after surgery,” notes lead author Stephanie Tuminello, MPH.

Opioid Use after Lung Cancer Surgery

In spite of the intention for opioids to be only a short-term fix, three to six months later, more than 15 percent of the lung cancer patients were still taking those opioid medications. Notably, those who underwent the more invasive type of surgery were much more likely to have become long-term opioid users.

“Our study suggests that surgical invasiveness might play a role in the odds of becoming a long-term opioid user after surgery,” writes Tuminello. “Patients undergoing VATS were less likely to use opioids both in the immediate postoperative period and long-term, even after adjusting for relevant covariates.”

Given the growing issue of opioid addiction in the US, the authors say more research is needed into how pain management after surgery could be contributing to the problem.

Minimally Invasive Mesothelioma Surgery

Although the current study does not directly address the issue of opioid use among mesothelioma patients, treatment similarities between lung cancer and pleural mesothelioma suggest the results are relevant.

Fortunately, minimally invasive options for mesothelioma treatment are in development.

Earlier this month, Japanese doctors reported their success treating recurrent pleural mesothelioma with a minimally invasive radiofrequency ablation technique normally used to alleviate pain.

Last year, a team of Chinese researchers declared VATS surgery (also called thoracoscopy) “valuable and safe” for mesothelioma diagnosis and symptom management after evaluating more than 800 patients with pleural cancers.

Two additional studies in 2018 led by Spanish researchers confirm the feasibility and safety of a minimally invasive CRS/HIPEC technique for the treatment of small peritoneal mesothelioma tumors.

Source:

Tuminello, S, et al, “Video-Assisted Thoracoscopic Surgery for early-Stage Lung Cancer”, September 24, 2018, JAMA Oncology, Epub ahead of print

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…